<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: [(18)F]EF5 is a validated marker for PET imaging of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0005039'>hypoxia</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>It is prepared by reacting a trifluoroallyl precursor with carrier-added [(18)F]F(2) gas in <z:chebi fb="0" ids="45892">trifluoroacetic acid</z:chebi> (TFA) solvent </plain></SENT>
<SENT sid="2" pm="."><plain>We report here an improved radiosynthesis and purification of [(18)F]EF5 by utilizing an electroformed <z:chebi fb="152" ids="28112">nickel</z:chebi> (Ni) target for [(18)F]F(2) production, and Oasis® HLB cartridges for on-line solid phase extraction of [(18)F]EF5 prior to HPLC purification </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: [(18)F]F(2) was produced by <z:chebi fb="1" ids="29233">deuteron</z:chebi> bombardment of neon plus F(2) in an Ni target, and bubbled through the radiolabelling precursor solution </plain></SENT>
<SENT sid="4" pm="."><plain>Purification was achieved by extracting the contents of the crude reaction mixture onto Oasis HLB cartridges, and subsequently eluted onto a semi-preparative HPLC column for further separation </plain></SENT>
<SENT sid="5" pm="."><plain>Purified [(18)F]EF5 was evaluated in small animal PET studies using HCT116 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts in <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The electroformed Ni target enabled recovery of &gt;75% of the radioactivity from the cyclotron target, resulting in 16.2 ± 2.2 GBq (438 ± 58 mCi) of [(18)F]F(2) available for the synthesis </plain></SENT>
<SENT sid="7" pm="."><plain>Use of Oasis cartridges yielded a less complex mixture for purification </plain></SENT>
<SENT sid="8" pm="."><plain>On average, 1140 ± 200 MBq (30.8 ± 5.4 mCi) of [(18)F]EF5 were collected at EOS </plain></SENT>
<SENT sid="9" pm="."><plain>Small animal PET imaging studies showed specific retention of [(18)F]EF5 in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-to-muscle ratios of 2.7 ± 0.3 at about 160 min after injection </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: A simple procedure has been developed for the routine synthesis of [(18)F]EF5 in amounts and purity required for clinical studies </plain></SENT>
<SENT sid="11" pm="."><plain>This new method avoids the need for TFA evaporation and also enables facile automation of the synthesis using commercially available radiosynthesis modules </plain></SENT>
</text></document>